In cancer pathologies, CD8+ T-cells will have increased homing to tumorigenic cells, and in cell lines expressing increased PD-L1, such as BC cells, PD-L1 can bind to PD-1 on CD8+ T-cells to downregulate the immune response, and thus increase BC progression (Figure 2). The gene discussed is PDCD1; the disease is cancer.